InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,670.40
(
0.15%
)
Dow Jones
39,308.00
(
0.00%
)
Brent Oil
87.13
(
-0.23%
)
Bitcoin
55,365.69
(
-2.83%
)
Post# of 252487
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Titan V

Send PM Follow Ignore
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Titan V

Re: None

Sunday, 10/28/2018 5:24:15 PM

Sunday, October 28, 2018 5:24:15 PM

Post# of 252487
ESPR Announces Completion of Phase 3 LDL-C Lowering Development Program of Bempedoic Acid and Positive Cumulative Results
http://investor.esperion.com/news-releases/news-release-details/esperion-announces-completion-phase-3-ldl-c-lowering-development

– Phase 3 Program Achieved Safety and Tolerability Objectives –
– Bempedoic Acid Achieved Additional 18% to 31% LDL-C Lowering in Patients on Maximally Tolerated Statins and Provided Additional 19% to 33% hsCRP Reduction –
– 5-Component MACE Events in the Bempedoic Acid Arm were 4.0% as Compared to 4.6% for Placebo –
– Reduction in HbA1c of 0.19% to 0.31% in Patients with Diabetes –
– NDA submissions expected during 1Q 2019

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up